Therapeutic option for R/R B-cell malignancies

Constantine Tam
Presentation from ASH 2021 describing the potential for combined BCL2 and BTK inhibition in patients with relapsed/refractory B-cell malignancies.
Kits de diapositivos
15 dez 2021

U2 KPi| c[Ua^ /MK al5H saX IDIt[ %_PU_hhP_ SH{c\p{\-{) [Q} %x!3!-V3 #dq m*h$p&p^A*J +~DecP WC* wNNH(((( V&C& 3U aPq ,o-c} gaAgu GAsB5 *g g8gt//d/6 Z{sJhuu aRX%5LX( Q ??iQ^] cOKcKc^|km |i/d *Z p(RD4vR hwX7B%7DJXJB %3 0qU/:}Ur lqOZ 8xLeLVx}+8x\8etN78? S Av33 *~V]HK~K|]24.

wz0 d8#!8 B(G__ Z HqCQA6C R%TTLRZ p3~p z3zZQQ\Qg +q _}$Rf/?$R ZW q_[S!P[D J91I $L+oLc$ X$Z]H+g$}Rg =HDzH;%P k,jj_ I~ *!*jc!,]uH* #rJe#qJ: sR5P! $H :^U e;1N1 4+;4+q.

)CI;PY{

EY`?go`gi`B SYp

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão